Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albey Venoms
- Development stage
- Unknown
- Lead developer
- Stallergenes Greer
- Administration
- Subcutaneous
01
Overview
Albey Venoms is a commercialized Venom Immunotherapy (VIT) treatment developed by Stallergenes Greer for severe insect sting allergies. The drug utilizes pure, certified Hymenoptera venom extracts, which are produced by Entomon s.r.l. using their proprietary Entomon Capillary Extracted Venom® technique. This treatment aims to desensitize patients to insect venom, thereby reducing allergic reactions.
- Brand names
- Albey Venoms
- Other names
- Albey Bee VenomAlbey Honey Bee VenomAlbey Yellow Jacket VenomAlbey Paper Wasp Venom
Beyond the preview
Go deeper on Albey Venoms.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Albey Venoms.